Pfizer says FDA okays arthritis drug
Pfizer says the Food and Drug Administration approved its rheumatoid arthritis pill Xeljanz, seen as potential big seller for the company.
Pfizer Inc. says the FDA approved Xeljanz as a treatment for moderate to severe rheumatoid arthritis in patients who can't take methotrexate or haven't been helped by it. Xeljanz is intended to slow the progression of the disease. The approval comes about two weeks sooner than expected.
Xeljanz, or tofacitinib, is the first rheumatoid arthritis treatment from a new class of pain medications called JAK inhibitors. The drugs interfere with enzymes that contribute to tissue inflammation.
- Associated Press
Stories that may interest you
Job Fair on Monday
Honda is slowing production of Accord sedans as car buyers continue to favor SUVs and trucks
Cultural monuments can be tough to value _ as the fire at Notre Dame has shown
President Donald Trump may soon be able to claim a sweet victory for his deregulation push: Officials are preparing to get rid of decades-old rules for frozen cherry pies
Easter Sunday bombings at churches, hotels kill more than 200 in Sri Lanka; 'several' Americans among dead7:37 pm